help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janssen, Y. J. H.
Right arrow Articles by Roelfsema, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janssen, Y. J. H.
Right arrow Articles by Roelfsema, F.
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 1 279-284
Copyright © 1999 by The Endocrine Society

Original Studies

Changes in Muscle Volume, Strength, and Bioenergetics during Recombinant Human Growth Hormone (GH) Therapy in Adults with GH Deficiency1

Y. J. H. Janssen, J. Doornbos and F. Roelfsema

Departments of Endocrinology (Y.J., F.R.) and Radiology (J.D.), Leiden University Medical Center, Leiden, The Netherlands

Address all correspondence and requests for reprints to: Dr. F. Roelfsema, Department of Endocrinology, Leiden University Medical Center, Albinusdreef 2, 2333 AA Leiden, The Netherlands. E-mail: roelfsema{at}rullf2.medfac.leidenuniv.nl

Adults with GH deficiency (GHD) suffer from muscle weakness, which can be caused by the frequently reported decrease in muscle mass. However, measurements of both muscle strength and mass of muscle tested are scarce in adults with GHD. The aim of the present study was, therefore, to investigate intrinsic muscle strength (strength expressed per muscle volume unit) in adults with GHD at baseline and after 52 weeks of recombinant human GH (rhGH) therapy given in low, more physiological doses. A second objective was to investigate the influence of GH on muscle bioenergetics in the resting muscle. Isometric and isokinetic quadriceps strengths were measured in 28 males with GHD and in healthy controls matched for age and height. Quadriceps mass, determined by magnetic resonance imaging, and muscle bioenergetics, determined by phosphorus nuclear magnetic resonance spectroscopy, were measured in 20 of 28 patients with GHD and in controls matched for age and height. All patients were treated with doses of rhGH ranging from 0.6–1.8 IU/day, given for 52 weeks. Measurements of muscle mass, strength, and bioenergetics were repeated after 52 weeks of treatment with rhGH. The mean GH dose at 52 weeks of rhGH treatment was 1.3 ± 0.8 IU/day. The mean serum insulin-like growth factor I level at baseline was 9.4 ± 0.7 nmol/L and significantly increased to 26.4 ± 1.2 nmol/L after 52 weeks of rhGH treatment. Adults with GHD had significantly reduced quadriceps muscle mass (P = 0.034) and reduced isometric muscle strength (P = 0.002) and tended to have low isokinetic muscle strength (P = 0.06), which all improved after rhGH therapy. Intrinsic muscle strength was not significantly different in adults with GHD compared with that in healthy controls and did not change during rhGH therapy. No bioenergetic abnormalities at baseline or after rhGH therapy were found in males with GHD. In conclusion, quadriceps muscle mass is decreased in adults with GHD and increased with rhGH therapy. These changes in muscle mass account for the changes in muscle strength found in these patients, as no changes in intrinsic muscle strength were found.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
G. Gotherstrom, M. Elbornsson, K. Stibrant-Sunnerhagen, B.-A. Bengtsson, G. Johannsson, and J. Svensson
Ten Years of Growth Hormone (GH) Replacement Normalizes Muscle Strength in GH-Deficient Adults
J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 809 - 816.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Gibney, M.-L. Healy, and P. H. Sonksen
The Growth Hormone/Insulin-Like Growth Factor-I Axis in Exercise and Sport
Endocr. Rev., October 1, 2007; 28(6): 603 - 624.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat
The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults
Endocr. Rev., May 1, 2006; 27(3): 287 - 317.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Molitch, D. R. Clemmons, S. Malozowski, G. R. Merriam, S. M. Shalet, M. L. Vance, and for The Endocrine Society's Clinical Guidelines Su
Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1621 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Kim, E. Barton, N. Muja, S. Yakar, P. Pennisi, and D. LeRoith
Intact Insulin and Insulin-Like Growth Factor-I Receptor Signaling Is Required for Growth Hormone Effects on Skeletal Muscle Growth and Function in Vivo
Endocrinology, April 1, 2005; 146(4): 1772 - 1779.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A J van der Lely
Justified and unjustified use of growth hormone
Postgrad. Med. J., October 1, 2004; 80(948): 577 - 580.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. Schweizer, D. D. Martin, C. P. Schwarze, G. Binder, A. Georgiadou, J. Ihle, and M. B. Ranke
Cortical Bone Density Is Normal in Prepubertal Children with Growth Hormone (GH) Deficiency, but Initially Decreases during GH Replacement due to Early Bone Remodeling
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5266 - 5272.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. Liu, S. G. Thomas, S. L. Asa, N. Gonzalez-Cadavid, S. Bhasin, and S. Ezzat
Myostatin Is a Skeletal Muscle Target of Growth Hormone Anabolic Action
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5490 - 5496.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Svensson, K. Stibrant Sunnerhagen, and G. Johannsson
Five Years of Growth Hormone Replacement Therapy in Adults: Age- and Gender-Related Changes in Isometric and Isokinetic Muscle Strength
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2061 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet
Optimizing GH Therapy in Adults and Children
Endocr. Rev., August 1, 2001; 22(4): 425 - 450.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. C. Hoeck, P. Vestergaard, P. E. Jakobsen, J. Falhof, and P. Laurberg
Diagnosis of Growth Hormone (GH) Deficiency in Adults with Hypothalamic-Pituitary Disorders: Comparison of Test Results Using Pyridostigmine Plus GH-Releasing Hormone (GHRH), Clonidine Plus GHRH, and Insulin-Induced Hypoglycemia as GH Secretagogues
J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1467 - 1472.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
Measures of Submaximal Aerobic Performance Evaluate and Predict Functional Response to Growth Hormone (GH) Treatment in GH-Deficient Adults
J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4570 - 4577.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1999 by The Endocrine Society